SCHEMBL30063495

SCHEMBL30063495

CCCCOC(=O)N1CC2(CC(CCN)C2)C1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ GBA2 Q9HCG7 1/20 0.35
▸ HRH2 P25021 1/20 0.34
▸ HRH1 P35367 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ BCHE P06276 1/20 0.34
▸ GPR119 Q8TDV5 3/20 0.34
▸ P2RY12 Q9H244 3/20 0.33
▸ HTR2C P28335 1/20 0.33
▸ ATM Q13315 1/20 0.33
▸ PLA2G2A P14555 2/20 0.32
▸ OPRD1 P41143 1/20 0.32
▸ OPRK1 P41145 1/20 0.32
▸ EPHX2 P34913 1/20 0.32
▸ NAAA Q02083 1/20 0.32
▸ SMYD3 Q9H7B4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31282074 0.88 LMNA (0.44) LMNAPOLBSMN1; SMN2GBA2HRH2
SCHEMBL23859720 0.81 LMNA (0.49) LMNAPOLBSMN1; SMN2GBA2HRH2
SCHEMBL30013395 0.80 LMNA (0.48) LMNAPOLBSMN1; SMN2GBA2HRH2
SCHEMBL30376526 0.80 LMNA (0.43) LMNAPOLBSMN1; SMN2GBA2HRH2
SCHEMBL31365786 0.80 LMNA (0.43) LMNAPOLBSMN1; SMN2GBA2HRH2
SCHEMBL30467459 0.79 LMNA (0.47) LMNAPOLBSMN1; SMN2GBA2HRH2
SCHEMBL31532476 0.78 LMNA (0.41) LMNAPOLBSMN1; SMN2GBA2HRH2
SCHEMBL18639389 0.78 LMNA (0.46) LMNAPOLBSMN1; SMN2GBA2HRH2
SCHEMBL30177247 0.77 LMNA (0.44) LMNAPOLBSMN1; SMN2GBA2HRH2
SCHEMBL22835443 0.76 GPR119 (0.42) SMN1; SMN2GPR119EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4333836-A1 DEUTERATED IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-03-13 — — EP disclosed
WO-2022236339-A1 DEUTERATED IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2022-11-10 — — WO disclosed
Send feedback